{"name":"Theravance Biopharma","slug":"theravance-biopharma","ticker":"TBPH","exchange":"NASDAQ","domain":"theravance.com","description":"Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.","hq":"South San Francisco, CA","founded":0,"employees":"90","ceo":"","sector":"Respiratory / Neurology","stockPrice":16.62,"stockChange":-0.05,"stockChangePercent":-0.3,"marketCap":"$857M","metrics":{"revenue":109775000,"revenueGrowth":15,"grossMargin":71,"rdSpend":37414000,"netIncome":105895000,"cash":394665984,"dividendYield":0,"peRatio":7.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TD-1607","genericName":"TD-1607","slug":"td-1607","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TD-1607","genericName":"TD-1607","slug":"td-1607","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOaGZpc2lURHBrWG80eGYtS1RPLThVQmZOWW5aajlyTnpsLTNyM2RWUDJLWUJyRVZBRmxKN0tseEtEc1ZORWNtNVRtQzZrWXBkVjNtME1TUkRUaXJZVU91M1FNOS1IeDd5ZTJKbmh4ZUs1a1d4ZW9tdU04RzZNNzFlOWNPRDZMai1NWFB5bzVGQm9pVmJ6VlRYZ1Zvc0NwMF9IcnBFY3IxUWF1c3hYMS1GTw?oc=5","date":"2026-04-06","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Ther","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE01U2JMSUcxX1ZIQlZRVmNMcGVXWFU5MjNDNXBDUFhlU3lWLXNwYkJfY3Fha3JyU29hNDUwWi1LbTRsMU9VYmpVeFhQY0QtMDE3Y1FwdkRwV1ZkWkFaNFNGV0drd9IBY0FVX3lxTE01U2JMSUcxX1ZIQlZRVmNMcGVXWFU5MjNDNXBDUFhlU3lWLXNwYkJfY3Fha3JyU29hNDUwWi1LbTRsMU9VYmpVeFhQY0QtMDE3Y1FwdkRwV1ZkWkFaNFNGV0drdw?oc=5","date":"2026-04-06","type":"pipeline","source":"Bitget","summary":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics, and Avalo Therapeutics - Bitget","headline":"Zacks Industry Outlook Features Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therap","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxORGxFSnFkVFVFSzlUN3MtaVdwWUxMcldycVItejFGWHg3d2NDSXFheEFBUEtINXZNNjVjX3pUbkNCWWpxWXJQb28xVHFJNUNES1NBUHp4cFBFb1NrQzliT3FtallRaHIxRDh6YXl4U3hhandRZlhoVmxMekFVMF9pUG1FQWY0cTQ3WlU0UTgtREdTTWd2THBTSkZsZEJXOWwyODVEQmduSVNLd2U5N0pMNjZHeUZtcmprdThvdnFPMGM2aW5YdlhwUWtWM050RnVDLUxxVjNpeWpzQ0lDOWozX1VZOVVFTzMtM19UMWtBc2JVNHFIS2tYMnVpeDBDZjRQdzl2eUhZcnc1alBfSzJCNGk0Q3k5dEZGX0g0Z1NiOW04NWVzOVMtbFhWcFliWWhtMkIzQjQySmcwaV93dXJPY1F5c2xrdk1WUzZ6Q210Wktxdw?oc=5","date":"2026-04-03","type":"pipeline","source":"Barchart.com","summary":"Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro -","headline":"Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven ","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOSVZId0VidFhPZzQtanhNUG1CNmF3YzZ1SXYtalNMZGxYY0c4ZTU0S2NfN2stRENKckZKYUlEQmdDd1FpeUI4a0gyS0ZBeGpIVzJwOTAwdDZtdkFKVTZvTllCUE0yRW1FdGpKczUyb2psRzh5SVIzSFN1SlFVT05wZ0VaVmpNRXZyRC1uQ1dOQ1VEMG5FRDI0TGdMWW5yZw?oc=5","date":"2026-03-04","type":"pipeline","source":"The Pharma Letter","summary":"Share tumbles and jobs to go after Theravance failure - The Pharma Letter","headline":"Share tumbles and jobs to go after Theravance failure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPZlFHSXJCVlNIUUVEQXFnV1JURktBMGQ2TmVzczZVazZXcUxVR0VKVTVNcXFmMTZrRzNUYjU0UXpWSWF4c0JrS2FLNzZOalNtVlNNMnItZGRpb3pja3FXTTZJbzQtUGl2RmlhR0lHSHlmLUEwWG9DdldjWG1KYjBYb2tJWk5nM2V6RWJ3cFQ4WkVVRldEOEcxa211SXgySEJSbUlPMA?oc=5","date":"2026-03-03","type":"pipeline","source":"MedCity News","summary":"Theravance Drug Fails Another Pivotal Test, This Time Sparking Restructuring That Ends R&D - MedCity News","headline":"Theravance Drug Fails Another Pivotal Test, This Time Sparking Restructuring That Ends R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE04eURtUVhDck9wT2J1VFNDVGIzM2lTcmxjdFRHV0RjWFo5bHZqcUp1ZEhGNnhPS3B0dVY5NkRyb0ZDa1FvSEJzWFhqOUtJel9xWFRR?oc=5","date":"2026-03-03","type":"trial","source":"FirstWord Pharma","summary":"Theravance to cut staff by 50% after hypotension drug fails another study - FirstWord Pharma","headline":"Theravance to cut staff by 50% after hypotension drug fails another study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQcmFHY2x4NUo0OGdYcHZabmlfdFROdXhPT3JLcFk1U2M3NUpMRl91bV9KUDRSSTMxTHh2eG9mTDE5akhCSU04VUtRX1Byd085a0J2eVQ3bFdWVTVaLUZhQThKZ1lfbFUxYmVYQ0VJazN5MU5TLUJFeGdLRmp2UEEyYWZpamlQUlVqemt5VU56YTZ5SUFDNHFaY2Qxc3R1NzhSS2lKZlVrQk1oMmYwUXlLRW11UQ?oc=5","date":"2026-03-03","type":"trial","source":"Stock Titan","summary":"Phase 3 failure drives Theravance (NASDAQ: TBPH) restructuring and review - Stock Titan","headline":"Phase 3 failure drives Theravance (NASDAQ: TBPH) restructuring and review","sentiment":"negative"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2025-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQMU1UMnBtSHBzbGhxR0RINllCZDdpZ2NySWZ6Wm9rMjJYN0hMcThUUi1lckFoMzR4SmxMRXRURWFoNThrYUI4ZXoxMXNqYkFpRmNZVndocy01MGRoNGtEdHpiV0RPWjFxaXh2elp5Zkl1SE5pWW9sanBrcFVQSXZXSEdubks3cnN5bVo1MnZGb1VwMGZ0MjJjaFUzYTVwQzJIek9zSURJOA?oc=5","date":"2025-10-20","type":"trial","source":"Fierce Pharma","summary":"Theravance stands up nOH physician education campaign ahead of pivotal data - Fierce Pharma","headline":"Theravance stands up nOH physician education campaign ahead of pivotal data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQaVd2RUZVSFNZam9ROWlkR1hZNTBkYUZKVEV0QnpWd0VYZkNJcWpOOFRzX3VmODdvR0t6Vk1DNkxCVjh5RS1ZSmpCOEdwXzVQam5FX0RzS2oySTlBVXVNOVJsZ0otVGo5T2xhVldzN253NjlmSkJFeUtLUXZlNXBWb0VjWWcxeGxxWi1NVU1QYl8yQnduUWtDUHd4SkRFc2ZnanhxVGgzdzU4VTItUXo4Snh4Qno?oc=5","date":"2025-06-06","type":"patent","source":"msn.com","summary":"Theravance and Mylan settle patent dispute with Eugia Pharma - msn.com","headline":"Theravance and Mylan settle patent dispute with Eugia Pharma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":15386000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":15386000,"period":"2017-12-31"},{"value":4515000,"period":"2017-12-31"},{"value":4275000,"period":"2017-09-30"},{"value":3509000,"period":"2017-06-30"},{"value":3087000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":37414000,"rdSpendHistory":[{"period":"2025-12-31","value":37414000},{"period":"2024-12-31","value":37643000},{"period":"2023-12-31","value":40621000},{"period":"2022-12-31","value":63392000}],"sgaSpend":73652000,"operatingIncome":-3602000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-3602000},{"period":"2024-12-31","value":-42436000},{"period":"2023-12-31","value":-53292000},{"period":"2022-12-31","value":-79119000}],"netIncome":105895000,"netIncomeHistory":[{"period":"2025-12-31","value":105895000},{"period":"2024-12-31","value":-56418000},{"period":"2023-12-31","value":-55193000},{"period":"2022-12-31","value":872132000}],"eps":2.06,"epsHistory":[{"period":"2025-12-31","value":2.06},{"period":"2024-12-31","value":-1.15},{"period":"2023-12-31","value":-1},{"period":"2022-12-31","value":11.85}],"cash":167806000,"cashHistory":[{"period":"2025-12-31","value":167806000},{"period":"2024-12-31","value":37797000},{"period":"2023-12-31","value":39545000},{"period":"2022-12-31","value":298172000}],"totalAssets":485570000,"totalLiabilities":188847000,"totalDebt":42703000,"equity":296723000,"operatingCashflow":238541000,"operatingCashflowHistory":[{"period":"2025-12-31","value":238541000},{"period":"2024-12-31","value":-11535000},{"period":"2023-12-31","value":-26997000},{"period":"2022-12-31","value":-186991000}],"capex":-42000,"capexHistory":[{"period":"2025-12-31","value":-42000},{"period":"2024-12-31","value":-332000},{"period":"2023-12-31","value":-2488000},{"period":"2022-12-31","value":-572000}],"freeCashflow":238499000,"dividendsPaid":null,"buybacks":-4034000,"employees":90,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":18520000,"ebit":73650000,"ebitda":73846000,"period":"2025-12-31","revenue":45891000,"epsBasic":1.2,"netIncome":61024000,"rdExpense":7360000,"epsDiluted":1.15,"grossProfit":null,"operatingIncome":20011000},{"sga":18333000,"ebit":-2316000,"ebitda":-1680000,"period":"2025-09-30","revenue":19990000,"epsBasic":0.07,"netIncome":3615000,"rdExpense":8112000,"epsDiluted":0.07,"grossProfit":null,"operatingIncome":-6455000},{"sga":18430000,"ebit":73869000,"ebitda":74796000,"period":"2025-06-30","revenue":26195000,"epsBasic":1.09,"netIncome":54835000,"rdExpense":10490000,"epsDiluted":1.08,"grossProfit":null,"operatingIncome":-2725000},{"sga":18370000,"ebit":-13495000,"ebitda":-12443000,"period":"2025-03-31","revenue":15388000,"epsBasic":-0.27,"netIncome":-13579000,"rdExpense":11452000,"epsDiluted":-0.27,"grossProfit":null,"operatingIncome":-14434000},{"sga":18501000,"ebit":-8296000,"ebitda":-7601000,"period":"2024-12-31","revenue":18754000,"epsBasic":-0.31,"netIncome":-15527000,"rdExpense":9453000,"epsDiluted":-0.31,"grossProfit":null,"operatingIncome":-9200000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":16.62,"previousClose":16.67,"fiftyTwoWeekHigh":21.03,"fiftyTwoWeekLow":8.4,"fiftyTwoWeekRange":"8.4 - 21.03","fiftyDayAverage":15.71,"twoHundredDayAverage":16.17,"beta":0.19,"enterpriseValue":505226592,"forwardPE":12.3,"priceToBook":2.86,"priceToSales":7.81,"enterpriseToRevenue":4.6,"enterpriseToEbitda":76.83,"pegRatio":0,"ebitda":6576000,"ebitdaMargin":6,"freeCashflow":22506500,"operatingCashflow":268780992,"totalDebt":40504000,"debtToEquity":13.9,"currentRatio":13.14,"returnOnAssets":0.8,"returnOnEquity":50.2,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":17.2,"targetHighPrice":21,"targetLowPrice":15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.7,"institutionHeldPercent":99.2,"sharesOutstanding":51553005,"floatShares":24585628,"sharesShort":5159991,"shortRatio":12.29,"shortPercentOfFloat":10,"epsTrailing":2.23,"epsForward":1.35,"revenuePerShare":2.17,"bookValue":5.81,"officers":[{"age":65,"name":"Mr. Rick E. Winningham M.B.A.","title":"CEO & Director"},{"age":60,"name":"Ms. Rhonda F. Farnum","title":"Chief Business Officer and Senior VP of Commercial & Medical Affairs"},{"age":48,"name":"Dr. Aine  Miller Ph.D.","title":"Senior VP of Development & Head of Ireland Office"},{"age":43,"name":"Mr. Aziz  Sawaf C.F.A.","title":"Senior VP & CFO"},{"age":null,"name":"Mr. Stuart  Knight","title":"Senior VP of IT&I and Chief Information Officer"},{"age":51,"name":"Mr. Brett A. Grimaud Esq.","title":"Senior VP, General Counsel & Secretary"},{"age":null,"name":"Ms. Stacy L. Pryce","title":"Senior VP & Chief Strategy Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.theravance.com","phone":"650 808 6000"}}